Advances in the treatment of polyarticular juvenile idiopathic arthritis

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo2009 · 549 citations
2. 2Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study2008 · 545 citations
3. 3Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis2012 · 955 citations
4. 4Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype2010 · 57 citations